Skip to main content
logo
Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
3.150
+0.430 (15.81%)
Apr 13, 2026, 2:57 PM EDT - Market open

Allogene Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-0.020.10.16114.09
Revenue Growth (YoY)
--76.84%-39.10%-99.86%-
Gross Profit
-0.020.10.16114.09
Selling, General & Admin
56.7865.2171.6779.3174.11
Research & Development
150.15192.3242.91256.39220.18
Other Operating Expenses
2.3815.7213.25--
Total Operating Expenses
209.32273.22327.83335.69294.28
Operating Income
-209.32-273.2-327.74-335.54-180.19
Interest Income
19.2920.1518.314.571.71
Interest Expense
-1.08-0.18---
Other Non-Operating Income (Expense)
0.22-3.92-17.84-9.44-3.57
Total Non-Operating Income (Expense)
18.4316.050.47-4.88-1.86
Pretax Income
-190.89-257.15-327.27-340.41-182.05
Provision for Income Taxes
--0.44---
Net Income
-190.89-257.59-327.27-340.41-182.05
Net Income to Common
-190.89-257.59-327.27-340.41-182.05
Shares Outstanding (Basic)
221195157143136
Shares Outstanding (Diluted)
221195157143136
Shares Change (YoY)
13.25%24.14%9.63%5.39%12.83%
EPS (Basic)
-0.87-1.32-2.09-2.38-1.34
EPS (Diluted)
-0.87-1.32-2.09-2.38-1.34
Shares Outstanding
229.41212.21168.64144.44142.62
Free Cash Flow
-149.63-200.99-239.25-225.71-206.26
Free Cash Flow Per Share
-0.68-1.03-1.52-1.58-1.52
Gross Margin
-100.00%100.00%100.00%100.00%
Operating Margin
--1241810.00%-344986.00%-215087.00%-157.94%
Profit Margin
--1166840.00%-344489.00%-218214.00%-159.57%
FCF Margin
--913609.00%-251841.00%-144686.00%-180.79%
EBITDA
-196.96-259.56-313.54-321.24-169.74
EBITDA Margin
--1179820.00%-330040.00%-205924.00%-148.78%
EBIT
-209.32-273.2-327.74-335.54-180.19
EBIT Margin
--1241810.00%-344986.00%-215087.00%-157.94%
Effective Tax Rate
0.00%0.17%0.00%0.00%0.00%
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q